|Day's Range||0.22 - 0.23|
|52 Week Range||0.18 - 0.70|
|PE Ratio (TTM)||-2.80|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||0.44|
MELBOURNE, Australia, July 10, 2017-- Australian biopharmaceutical company, Immuron Limited, is pleased to announce safety and efficacy results of the interim analysis of its ongoing IMM-124E Phase II ...
MELBOURNE, Australia, June 08, 2017-- Australian biopharmaceutical company Immuron Limited, today announced the pricing of its initial public offering in the United States of 610,000 American Depository ...
Categories: Yahoo Finance Get free summary analysis Immuron Ltd. reports financial results for the half-year ended December 31, 2016. We analyze the earnings along side the following peers of Immuron Ltd. – Pharmaxis Ltd, Prima BioMed Ltd and Bionomics Ltd (PXS-AU, PRR-AU and BNO-AU) that have also reported for this period. Highlights Summary numbers: Revenues of AUD 0.70 ... Read more (Read more...)